H ypertension, a very common health problem worldwide, increases the risk for cardiorenal events and premature deaths. Lowering the blood pressure (BP) in patients with moderate to severe hypertension reduces the risk of cardiovascular events and mortality.
H ypertension, a very common health problem worldwide, increases the risk for cardiorenal events and premature deaths. Lowering the blood pressure (BP) in patients with moderate to severe hypertension reduces the risk of cardiovascular events and mortality. 1 However, the benefit of using antihypertensive drugs in patients with mild hypertension is unclear, and the optimum BP at which the most favorable outcomes can be achieved remains unresolved.
Several studies involving treated hypertensive subjects have observed a J-shaped association between achieved BP and risk of adverse outcomes, [2] [3] [4] [5] suggesting the existence of a BP threshold below which organ perfusion is impaired and the risk is increased. However, contrary to the J-curve hypothesis, a metaanalysis of cohort studies showed that the risk for cardiovascular mortality linearly increased from a BP of 115/75 mm Hg 6 ; moreover, recent meta-analyses of randomized trials suggested that lowering the systolic BP to <130 mm Hg may reduce the incidence of cardiovascular events and all-cause mortality. 7, 8 Because the J-curve phenomenon has been observed mostly in treated hypertensive subjects, there exists the possibility that the BP threshold for adverse effects is set at a higher level in hypertensive subjects, and excessive antihypertensive treatments may thus cause poor outcomes. However, there have been a few studies that compared BP-associated outcomes between the users and nonusers of antihypertensives, and a meta-analysis of individual-patient data from clinical trials reported that the J-shaped association could also be observed in placebo-treated subjects. 9 This meta-analysis had the limitation of different baseline characteristics of the included subjects when compared with the general population.
In this study, we assessed critical cardiorenal event rates and all-cause mortality according to BP and antihypertensive use and compared the BP-related risk across nonusers, irregular users, and active users, in a population-based cohort of Korean adults constructed from the National Health Insurance Service-Health Screening database (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) .
human subject confidentiality protocols may be sent to the data provision review committee of the National Health Insurance Sharing Service (http://nhiss.nhis.or.kr).
Subjects
For the present study, we constructed a retrospective populationbased cohort from the National Health Insurance Service-Health Screening database (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . The National Health Insurance Service-Health Screening is a sample database, which was established using the National Health Information Database and is available for research or statistical purposes from the National Health Insurance Service. 10 The database covers data from 2002 onwards and includes the reimbursement records of the National Health Insurance Service as well as the results of the nationwide health examinations generally performed at 2-year intervals. Details including the data resource profile, lists of database variables, and health examination details are published elsewhere. [10] [11] [12] A total of 514 866 subjects were selected from among 5.15 million citizens aged 40 to 79 years, who had undergone a medical health examination in 2002 to 2003, and were followed until December 31, 2015. In addition to the 521 subjects who were excluded because of missing BP data, 11 543 subjects who reported having a history of heart disease or stroke during the baseline examinations, or were diagnosed with chronic kidney disease between 2002 and 2003, and a further 10 262 subjects who died or in whom critical cardiorenal events occurred before January 1, 2006 were excluded to avoid confounding of the outcome risk because of preexisting conditions. Thus, a total of 492 540 subjects were included in the final analysis ( Figure  S1 in the online-only Data Supplement).
Subjects were classified into 3 groups according to antihypertensive use. We obtained information about antihypertensive use from reimbursement records using National Health Insurance Billing Codes (Table S1 ). We considered a subject as a nonuser when the total prescription days of antihypertensives was <90, an active user when the total prescription days was at least 90 and more than half of the followup days (from the initiation of antihypertensive use to death or the end of the study follow-up), and an irregular user when the total prescription days was at least 90 but less than half of the follow-up period.
All personal identifying information was removed before data collection. The institutional review board of Kangwon National University Hospital waived the need for informed consent because this study collected routinely recorded data, and approved the protocol of the present study (IRB File No, KNUH-2017-04-029).
BP and Covariates
BP and covariates were determined from the records of medical health examinations or the eligibility database of the National Health Insurance Service-Health Screening. During health examinations, the BP was measured using sphygmomanometers or oscillometric devices after 5 minutes of rest and was measured repeatedly using sphygmomanometers after at least 2 minutes in the case of BP >120/80 or 140/90 mm Hg. We collected BP records separately among nonusers, irregular users, and active users. For new users in whom antihypertensive treatments were initiated during the study follow-up, the BP measured before antihypertensive use were regarded as those for nonusers, and the BP measured after the start of antihypertensive use were regarded as those for active or irregular users.
Systolic BP, the primary exposure of interest, was divided into eight 10-mm Hg BP categories: <105, 105 to <115, 115 to <125, 125 to <135, 135 to <145, 145 to <155, 155 to <165, and ≥165 mm Hg. Diastolic BP, the secondary exposure of interest, was divided into 6 categories: <65, 65 to <75, 75 to <85, 85 to <95, 95 to <105, and ≥105 mm Hg. Other variables were also formatted and classified into consistent categories cholesterol level (<200, 200-<240, or ≥240 mg/dL), smoking (never smoker, former smoker, or current smoker), proteinuria (yes or no), and diabetes mellitus (yes or no). Categories for missing data were included for all these variables to minimize the loss of cases in the analysis.
Outcomes
Mortality was confirmed throughout the follow-up using death certificates from Statistics Korea. The causes of death on death certificates were coded using the International Classification of Diseases Tenth Revision (ICD-10). We identified death from cardiovascular or renal causes using predefined ICD-10 codes (Table S2) . We also identified critical care unit admission for cardiovascular or renal diseases, revascularization for myocardial infarction (ICD-10; I21, I22, I23, and I24) or stroke (ICD-10; I63, I64, I65, and I66), and end-stage renal disease with dialysis for ≥90 days or kidney transplantation (ICD-10; Z94.0). To do that, we used the record of the main diagnosis coded with the ICD-10 (Table S2) , and retrieved information about revascularization procedures (Table S3) , kidney transplantation, hemodialysis, and prescribed peritoneal dialysates (Table S4) , from NHI reimbursement records.
The primary outcome was a composite of death (or critical care unit admission) from cardiovascular or renal diseases, revascularization for myocardial infarction or stroke, and new-onset end-stage renal disease, whichever occurred first. Secondary outcomes included allcause mortality and each disease component of the primary outcome.
Statistical Analysis
The 1-year event rates were estimated according to BP and antihypertensive use. To obtain uniformly age-standardized event rates in person-years, the hazard ratios were multiplied by the mean of the age-specific rates of the reference group (nonusers with a systolic BP of 115 to <125 mm Hg or those with a diastolic BP of 75 to <85 mm Hg). Age-specific rates were calculated by dividing the number of events by the number of person-years in 8 categories of current age among the reference group, which were determined in each year of outcome observation.
Hazard ratios for adverse outcomes were estimated using timedependent Cox regression models. We computed a new (time-dependent) average of systolic BP at each observed follow-up time, to incorporate the changes in BP and antihypertensive use over time. We averaged BP for (1) each time period from 2002 to the BP indicates blood pressure. *The number of person-years and events were calculated according to the systolic BP and antihypertensive use in each year of outcome observation. †Coronary end point was a composite of death (or critical care unit admission) from ischemic heart diseases and revascularization for myocardial infarction. ‡Cerebrovascular end point was a composite of death (or critical care unit admission) from cerebrovascular diseases and revascularization for stroke. §Other cardiovascular end point was a composite of death (or critical care unit admission) from other cardiovascular diseases. ‖Renal end point was a composite of death (or critical care unit admission) from chronic kidney diseases and occurrence of end-stage renal disease. (Table S5) or fasting glucose levels ≥126 mg/dL at least twice on blood tests, and proteinuria was defined as cases with a result of ≥trace at least twice on urine tests, which were generally biennially performed through 2015.
In all the models, 8 systolic BP categories among 3 user groups were entered altogether as a time-varying covariate: that is, a combined variable with 24 categories of systolic BP was entered as a covariate. The variables of income level, body mass index, total cholesterol level, exercise frequency, and alcohol consumption, which were categorized by using time-averaged values, and the current status of age, smoking, proteinuria, and diabetes mellitus were also included as time-varying covariates. Sex was entered as a fixed covariate. We additionally constructed the Cox models with a timevarying covariate of diastolic BP replacing systolic BP.
The analyses were conducted in all subjects combined and in subgroups stratified according to age, sex, or the presence of diabetes mellitus, at the year of outcome observation. We performed further analyses restricted to new active users with systolic BP ≥135 mm Hg before antihypertensive use. Statistical analyses were conducted using SAS (version 9.4; SAS Institute, Cary, NC) and SPSS (version 23.0; SPSS Inc, Chicago, IL); both software packages were confirmed to yield the same results. Table 1 shows the characteristics of the study subjects according to the use of antihypertensive drugs at baseline (on January 1, 2006). The median age was 54 years (interquartile range, 48-63 years) and the proportion of women was 46.0%. Compared with nonusers, antihypertensive users were older and demonstrated higher proportions of overweight, hypercholesterolemia, proteinuria, and diabetes mellitus. When compared with Figure 1 . Yearly rates of the primary outcome according to blood pressure (BP) and antihypertensive use. The primary outcome was a composite of death (or critical care unit admission) from cardiovascular or renal causes, revascularization for myocardial infarction or stroke, and new-onset end-stage renal disease. The 1-y rates were estimated by multiplying the hazard ratios of the primary outcome by the mean of the age-specific rates of the reference group. Hazard ratios were estimated using time-dependent Cox models while accounting for BP and antihypertensive use. The nonusers with a systolic BP of 115 to <125 mm Hg or a diastolic BP of 75 to <85 mm Hg at each time point served as the reference. All analyses were adjusted for age, sex, income level, physical exercise, smoking, alcohol consumption, body mass index, total cholesterol, proteinuria, and diabetes mellitus. irregular users, active users were of similar age but demonstrated higher proportions of proteinuria and diabetes mellitus.
Results

Baseline Characteristics
Cardiorenal Events and Mortality
A total of 33 550 deaths were noted over the 4 518 833 personyears of outcome observation (Table 2) . Critical cardiorenal events, the primary outcome, occurred in 26 122 subjects during 4 437 911 person-years. In addition to the 143 987 users who had received antihypertensives before January 1, 2006, 98 569 subjects started receiving antihypertensive drugs thereafter.
Among nonusers of antihypertensives, the risk for the primary outcome increased linearly from a BP of 105/65 mm Hg (Figure 1 ; Table S6 ), and the risk for all-cause mortality increased progressively as the BP increased >115/75 or 125/75 mm Hg (Figure 2 ; Table S7 ). Among irregular users, the risk for the primary outcome and all-cause mortality increased as the BP increased >115/75 mm Hg and 125/75 or 135/85 mm Hg, respectively. Among active antihypertensive users, the associations between BP and risk of overall outcomes were J-shaped. The risk for the primary outcome increased in systolic BP <115 mm Hg and >135 or 145 mm Hg, and in diastolic BP <65 mm Hg and >85 mm Hg. The risk for all-cause mortality increased in systolic BP <125 mm Hg and >135 or 145 mm Hg, and in diastolic BP <75 mm Hg and >85 mm Hg.
We also estimated the risk for each component of the primary outcome. Among nonusers, the risk for specific outcomes increased from a BP of 105/65 mm Hg ( Figure 3 ; Figure S2 ; Table S8 ). Among active users, the risks for coronary, cerebrovascular, and renal end points were lowest at systolic BPs of 125 to <145 mm Hg, 115 to <125 mm Hg, and <115 mm Hg, respectively, and at diastolic BP of 75 to <95 mm Hg, 65 to <85 mm Hg, and <75 mm Hg, respectively.
When we performed subgroup analyses, the J-shaped associations between BP and risk of overall outcomes persisted in active users stratified according to age, sex, or the presence of diabetes mellitus ( Figure 4 ; Figure S3 ; Tables S9  and S10 ). The J-curves were also observed in new active users with systolic BP >135 mm Hg before antihypertensive use ( Figure S4 ; Table S11 ).
Discussion
In this population-based cohort, the associations between BP and overall outcomes were J-shaped among active antihypertensive users, whereas the associations were linear or flat and then increasing among nonusers or irregular users. To date, the J-shaped relationship has been considered as a specific finding observed in patients with conditions such as coronary artery disease, 5 because most population-based cohorts have shown linear associations between BP and adverse outcomes. However, the present study demonstrated that excessive lowering of BP by antihypertensive drugs was associated with an increased risk of adverse outcomes in persons without noticeable cardiovascular or renal diseases, although the BP-related risk still increased linearly in those not receiving antihypertensive drugs. In the present study, the associations between BP and adverse outcomes were linear among nonusers of antihypertensives. Several cohort studies have reported that cardiovascular risk increases linearly from a threshold within the normal or below-normal range of BP. A population-based study showed that baseline systolic BP was linearly associated with all-cause and cardiovascular mortality in younger and elderly persons. 13 Among a total of 7830 subjects in that study, 83.3% had not received antihypertensive drugs at baseline. Likewise, a large meta-analysis of prospective observational studies, involving a total of 1 million persons, showed that the risk for all-cause and cardiovascular mortality progressively increased from a BP of 115/75 mm Hg. 6 The meta-analysis did not account for antihypertensive use, and the analyzed observational studies might include large numbers of subjects not receiving antihypertensives. Considering the present findings, we think that the linear associations observed in observational studies are derived from nonusers rather than from antihypertensive users.
In contrast, a meta-analysis of individual-patient data from clinical trials reported that the J-curve was found in untreated or placebo-treated persons as well as in actively treated persons. 9 The analysis investigated follow-up BP among hypertensive persons and found that persons with BP in the normal or below-normal range had an increased risk for mortality. The BP drop in untreated hypertensive persons, an unusual finding, could have a serious cause different from that in actively treated persons, and the increased risk would result from the serious cause (ie, reverse causality). However, most of the nonusers with normal or low normal BP in our cohort would have similar BP at or before the study entry and had a low risk for cardiorenal events.
Among active antihypertensive users without clinical cardiovascular or renal diseases, the associations between BP and overall outcomes were found to be J-shaped in our study. The risk for composite cardiorenal events and all-cause mortality increased in systolic BP <115 mm Hg and 125 mm Hg, respectively, and the proportions of those BP were 5.3% and 22.2%, respectively (Table 2) However, recent meta-analyses reported that the risk reductions from BP lowering were substantial even in trials with baseline systolic BP <130 mm Hg, 7 and the risk was lowest in groups with achieved systolic BP of 120 to 124 mm Hg. 8 The meta-analyses had a limitation that subject characteristics were different between involved trials: for example, lower baseline BP in trials of subjects with cardiovascular diseases than in those without. The effect of BP lowering in patients with cardiovascular diseases could be different from that in persons without cardiovascular diseases.
A recent randomized study of 12 705 adults at intermediate risk with a mean BP of 138/82 mm Hg, who did not have cardiovascular disease or marked kidney dysfunction, showed no benefit from using candesartan plus hydrochlorothiazide compared with the placebo (the HOPE-3 trial [Heart Outcomes Prevention Evaluation-3]). 16 Moreover, the ACCORD study (Action to Control Cardiovascular Risk in Diabetes) that involved 4733 patients with type 2 diabetes mellitus showed no beneficial effect of targeting systolic BP <120 mm Hg, as compared with 140 mm Hg. 17 Overall, these findings including ours support (or at least do not oppose) that targeting normal BP has no substantial benefit when using antihypertensive drugs in persons without cardiovascular or renal diseases, irrespective of the presence of comorbid diabetes mellitus.
On the other hand, this study showed diverse associations between actively treated BP and risk of specific outcomes. The specific risk for cerebrovascular or renal end point was lowest in the normal or below-normal BP groups, whereas the risk for coronary end point or all-cause mortality was lowest in the relatively high BP. These suggest that certain patients with a particular risk for end-stage renal disease or stroke might benefit from targeting normal BP. However, further studies are required to evaluate who is most likely to develop these end points and to have an overall benefit from strict BP control by antihypertensive use.
Remarkably, the SPRINT trial (Systolic Blood Pressure Intervention Trial) that involved 9361 persons with high cardiovascular risk, but without diabetes mellitus, showed that targeting systolic BP <120 mm Hg, as compared with 140 mm Hg, was associated with a reduction in the risk for cardiovascular event and all-cause mortality. 18 The SPRINT study had several distinctive features. At baseline, 28.3% and 20.1% of the 9361 persons had chronic kidney diseases and cardiovascular diseases (versus no noticeable renal disease or cardiovascular disease in our study and HOPE-3), respectively, and the mean urine albumin to creatinine ratio was 43 mg/g (versus 14 mg/g, the median in ACCORD). In particular, BP in SPRINT was measured 3× at 1-minute intervals via automated devices, after 5 minutes of rest in a quiet room. The automated measurement system yield BP lower than conventional methods; systolic BP ≈15 mm Hg lower than manual measurements and ≈7 mm Hg lower than daytime ambulatory monitoring. 19, 20 Therefore, the differences in BP measurements and comorbid diseases could explain the different findings between the present study and SPRINT.
There have been many debates about the J-shaped relationship: reverse causality because of underlying heart diseases, 21, 22 lack of adjustments for confounders in some studies reporting the existence of a J-shaped curve, 23, 24 and reports that low BP at baseline rather than during follow-up was associated with an increased risk. 25, 26 However, the present study excluded subjects who had clinical cardiovascular or renal diseases at baseline, the analyses were adjusted for various risk factors, and the J-curve was also observed in new active users with prior systolic BP >135 mm Hg. Furthermore, the relationship was linear or flat and then increasing among irregular users, in whom the risk for adverse outcomes was highest, as well as among nonusers. Therefore, reverse causality could not readily explain the J-curve observed among active users, and there's a possibility that excessive lowering of BP by antihypertensive drugs would causally increase the risk for cardiovascular events and all-cause mortality.
There are several concerns or limitations to consider. First, as mentioned above, the method of BP measurement should be considered to apply our findings to clinical practice, because the BP obtained via ambulatory or home measurements and obtained automatically with the patient alone in a waiting room is generally lower than the BP obtained on routine clinical measurement. 27 Second, some subjects did not undergo health examinations regularly despite the recommendation of undergoing examinations, generally at 2-year intervals. Among the survivors, 66.0%, 71.8%, 76.7%, 78.4%, 76.7%, and 78.2% (Table S12 ). In addition, caution is required to generalize these findings to other populations, as the present study included subjects who had no clinical cardiovascular or renal disease and resided in South Korea. Finally, given the observational nature of this study, it may be difficult to set precise targets for BP. Randomized trials are required to determine BP targets conclusively. In particular, clinical trials are required to evaluate in whom antihypertensive treatment targeting normal BP is distinctively beneficial.
Perspectives
These data suggest that lowering BP to normal or below-normal levels has no substantial benefit or may even be harmful when using antihypertensive drugs in persons without noticeable cardiovascular or renal diseases. However, nonpharmacologic therapy should be emphasized in persons even with mildly elevated BP, and further investigations are warranted to identify persons with specific risk factors who are likely to benefit from strict BP control.
